# Use of Non-Insulin Agents  in Hospitalized Patients with Type 2 diabetes (T2D)

> **NIH NIH K23** · EMORY UNIVERSITY · 2022 · $177,118

## Abstract

Abstract
Observational and prospective studies have reported on the association between hyperglycemia
in the hospital and higher rates of hospital complications, mortality, and longer length of stay.
Insulin therapy has been demonstrated to be effective in improving glycemic control and
reducing complications among hospitalized patients. Insulin use, however, is associated with
high rates of hypoglycemia, is cumbersome to administer (up to 4 injections daily), prone to
error if not administered at appropriate times and may not inform optimal treatment for
discharge. Several randomized controlled trials have demonstrated safety and efficacy of non-
insulin therapies in the management of hyperglycemia in the hospital. No studies to date,
however, have systematically evaluated a broad range of oral antidiabetic drugs (OAD) in the
hospital setting. Accordingly, we propose a randomized controlled pragmatic clinical trial to
compare continuation of home OADs to basal bolus insulin among hospitalized patients
admitted to non-ICU services. Our goal is to determine whether OADs in patients with mild to
moderate hyperglycemia can be continued during hospitalization to achieve similar glycemic
control to basal bolus insulin without leading to increased hospital complications or higher costs.
The findings of this real-world study will directly inform clinical care in the management of
diabetes in the hospital.
In addition, this proposal will enhance the multifaceted research training and career
development plan necessary for Dr. Fayfman to become an independent clinical investigator.
Dr. Fayfman will continue to work alongside an experienced mentoring and advisory team with
expertise in clinical trials in hospital settings, biostatistics, and health economics. This training is
supported by an institutional commitment to establishing interdisciplinary research
collaborations and advancing Dr. Fayfmans’ career in academic research.

## Key facts

- **NIH application ID:** 10378149
- **Project number:** 5K23DK124647-03
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Maya Fayfman
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $177,118
- **Award type:** 5
- **Project period:** 2020-06-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10378149

## Citation

> US National Institutes of Health, RePORTER application 10378149, Use of Non-Insulin Agents  in Hospitalized Patients with Type 2 diabetes (T2D) (5K23DK124647-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10378149. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*